Related Experiment Video
Updated: Jun 30, 2026

Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation
Published on: May 4, 2018
Systemic pilocarpine for treatment of xerostomia
1Moffitt Cancer Center at Tampa General Hospital, Moffitt Cancer Center, Radiation Oncology, 2 Columbia Dr, Tampa, FL 33606, USA. lawrence.berk@moffitt.org
Background:
Xerostomia is the feeling of dryness in the mouth, usually owing to hypofunctioning of the salivary glands. Causes of xerostomia include medications, the effects of radiation therapy on the salivary glands during the treatment of head and neck cancer or thyroid cancer, and autoimmune diseases such as Sjögren's syndrome. The primary treatment to reduce xerostomia is oral pilocarpine.
Objective:
This review discusses the randomized trials available on the efficacy and tolerability of oral pilocarpine for the treatment of xerostomia.
Methods:
The randomized trials of pilocarpine for xerostomia available in the medical literature are reviewed.
Results/Conclusion:
Pilocarpine has some efficacy in the treatment of xerostomia from radiation therapy, graft-versus-host disease and Sjögren's syndrome. It has limited activity for the prevention of xerostomia during radiation therapy. It may have increased efficacy in combination with newer forms of radiation therapy.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Ophthalmic Drug Delivery Systems
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Cholinergic Antagonists: Pharmacokinetics
